Veritas Pharma Inc. is an emerging global pharmaceutical company based out of Vancouver, Canada that’s investing in the discovery, product development and commercialization of effective, patented cannabis therapies that target disease conditions in the areas of chronic pain, senior long-term care and palliative care.
Through its subsidiary company, Cannevert Therapeutics Ltd., it aims to obtain comprehensive scientific evidence, for health care professionals and patients so that they can utilize these strains with confidence of a reliable therapeutic effect. Cannevert is made up of a strong management team, bringing together veteran academic pharmacologists, anesthetists and chemists, and each contributing to the critical need for preclinical and clinical data to support medical cannabis claims. It also has a Health Canada Dealer License, enabling it to import cannabis products from any part of the World as well as produce extracts for sell to Canadian licensed producers and aboard through an export permit. This allows Veritas to establish and promote globally the Cannevert brand of cannabis-based medicines.
Veritas’ investment in partnerships such as 3 Carbon Extractions Inc. and BioCan Technologies Inc., will enable it to codevelop cannabis extracts and delivery devices using not only Cannevert’s proprietary cannabis strains for upcoming clinical trials but also create newer strains that can address more unmet medical needs.
Veritas Pharma is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.